Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.54 |
| ▸ | HRH2 | P25021 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694161 | 1.00 | P2RY12 (0.54) | P2RY12HRH2HRH1 | |
| SCHEMBL523727 | 0.89 | CTSK (0.50) | P2RY12HRH2HRH1 | |
| SCHEMBL523554 | 0.89 | HRH2 (0.49) | P2RY12HRH2HRH1 | |
| SCHEMBL523553 | 0.89 | HRH2 (0.49) | P2RY12HRH2HRH1 | |
| SCHEMBL523726 | 0.89 | CTSK (0.50) | P2RY12HRH2HRH1 | |
| SCHEMBL524046 | 0.86 | HRH2 (0.50) | P2RY12HRH2HRH1 | |
| SCHEMBL524045 | 0.86 | HRH2 (0.50) | P2RY12HRH2HRH1 | |
| SCHEMBL316793 | 0.85 | HRH2 (0.57) | P2RY12HRH2HRH1 | |
| SCHEMBL316794 | 0.85 | HRH2 (0.57) | P2RY12HRH2HRH1 | |
| SCHEMBL524844 | 0.84 | HRH2 (0.60) | P2RY12HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664203-B2 | Thiazole derivatives and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885HRH2 324/4885HRH1 738/4885 |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885HRH2 297/4885HRH1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.